Md Zahidul I Pranjol
Overview
Explore the profile of Md Zahidul I Pranjol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aljarrah D, Chalour N, Zorgani A, Nissan T, Pranjol M
Biomed Pharmacother
. 2024 Mar;
173:116420.
PMID: 38471271
Gut microbiome alterations are associated with various cancers including brain tumours such as glioma and glioblastoma. The gut communicates with the brain via a bidirectional pathway known as the gut-brain...
2.
Taha A, Taha-Mehlitz S, Nadyrov E, Zinovkin D, Veyalkin I, Levin L, et al.
JAMA Netw Open
. 2023 Aug;
6(8):e2329559.
PMID: 37589974
Importance: To our knowledge, there are no complete population-based studies of the risks of developing second malignant tumors after papillary thyroid carcinoma (PTC) in patients following the Chernobyl nuclear accident....
3.
Tillman L, Tabish T, Kamaly N, Moss P, El-Briri A, Thiemermann C, et al.
Biomater Biosyst
. 2023 Feb;
6:100047.
PMID: 36824160
In the diabetic kidneys, morbidities such as accelerated ageing, hypertension and hyperglycaemia create a pro-inflammatory microenvironment characterised by extensive fibrogenesis. Radiological techniques are not yet optimised generating inconsistent and non-reproducible...
4.
Ileiwat Z, Tabish T, Zinovkin D, Yuzugulen J, Arghiani N, Pranjol M
Front Immunol
. 2022 Sep;
13:976677.
PMID: 36045675
The tumour vasculature is well-established to display irregular structure and hierarchy that is conducive to promoting tumour growth and metastasis while maintaining immunosuppression. As tumours grow, their metabolic rate increases...
5.
Taha A, Taha-Mehlitz S, Petzold S, Achinovich S, Zinovkin D, Enodien B, et al.
Molecules
. 2022 Feb;
27(3).
PMID: 35163861
The aim of this study is to reveal the potential roles of apoptosis markers (Bcl2 and p53), proliferation markers (Ki-67 and CyclD1), and the neuroendocrine marker Chromogranin A as markers...
6.
Butnariu A, Look A, Grillo M, Tabish T, McGarvey M, Pranjol M
Interface Focus
. 2021 Dec;
12(1):20200081.
PMID: 34956606
In this review, we reveal the latest developments at the interface between SARS-CoV-2 and the host cell surface. In particular, we evaluate the current and potential mechanisms of binding, fusion...
7.
Broadway R, Patel N, Hillier L, El-Briri A, Korneva Y, Zinovkin D, et al.
Life (Basel)
. 2021 Aug;
11(8).
PMID: 34440532
Epithelial ovarian cancer (EOC) is one of the most common causes of cancer-related deaths among women and is associated with age and age-related diseases. With increasing evidence of risks associated...
8.
Pranjol M, Zinovkin D, Maskell A, Stephens L, Achinovich S, Los D, et al.
J Transl Med
. 2019 Jul;
17(1):216.
PMID: 31269957
Background: New treatment options for metastasised high-grade serous carcinoma (HGSC) are urgently needed. HGSC frequently metastasises to the omentum, inducing angiogenesis in the local omental microvasculature to facilitate tumour growth....
9.
Tabish T, Pranjol M, Horsell D, Rahat A, Whatmore J, Winyard P, et al.
Cancers (Basel)
. 2019 Mar;
11(3).
PMID: 30845739
Overexpression and secretion of the enzymes cathepsin D (CathD) and cathepsin L (CathL) is associated with metastasis in several human cancers. As a superfamily, extracellularly, these proteins may act within...
10.
Pranjol M, Gutowski N, Hannemann M, Whatmore J
Curr Cancer Drug Targets
. 2018 Sep;
19(3):231-242.
PMID: 30173647
Background: Metastasis still remains the major cause of therapeutic failure, poor prognosis and high mortality in epithelial ovarian cancer (EOC) patients. Previously, we showed that EOC cells secrete a range...